A Phase 2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sotatercept (MK-7962) in Children From 1 to Less Than 18 Years of Age With PAH on Standard of Care
Latest Information Update: 26 Mar 2025
At a glance
- Drugs Sotatercept (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Acronyms MOONBEAM
- Sponsors Merck Sharp & Dohme Corp.
- 24 Jan 2023 Status changed from not yet recruiting to recruiting.
- 06 Jan 2023 Planned initiation date changed from 4 Jan 2023 to 20 Jan 2023.
- 20 Dec 2022 Planned initiation date changed from 19 Dec 2022 to 4 Jan 2023.